IL1B and gout: Recently, the result of the CANTOS clinical trial testing the use of Canakinumab monoclonal anti-IL1b antibody in gout patients has shown a reduction in cardiovascular events, therefore providing further support to the link between excessive inflammatory response and increased CVR36.